Adherence to treatment with second-line therapies, dasatinib and nilotinib, in patients with chronic myeloid leukemia

References

• Goldman J, Melo J. Chronic myeloid leukemia – advances in biology and new approaches to treatment. N Engl J Med 2003;349(15):1451-64
   Google Scholar
• Kurzrock R, Kantarjian H, Druker B, Talpaz M. Philadelphia chromosome-positive leukemias: from basic mechanisms to molecular therapeutics. Ann Intern Med 2003;138:819-30
   PubMed Web of Science ®Google Scholar
• General Information About Chronic Myelogenous Leukemia: For Professionals, 2011. Available at: http://www.cancer.gov/cancertopics/pdq/treatment/CML/HealthProfessional [Last accessed 11 March 2011]
   Google Scholar
• General Information about Chronic Myelogenous Leukemia: For Patients, 2011. Available at: http://www.cancer.gov/cancertopics/pdq/treatment/CML/Patient/page1 [Last accessed 11 March 2011]
   Google Scholar
• American Cancer Society. Leukemia – Chronic Myeloid (Myelogenous), 2010. Available at: http://www.cancer.org/Cancer/Leukemia-ChronicMyeloidCML/DetailedGuide/leukemia-chronic-myeloid-myelogenous-key-statistics [Last accessed 15 September 2010]
   Google Scholar
• Cortes J. Hematol Oncol. Hematol Oncol Clin N Am. 2004;18:569-84
   PubMed Web of Science ®Google Scholar
• White P, Walker P. Chronic leukemias. In: Skeel R, ed. Handbook of Cancer Chemotherapy, 7th edn. Philadelphia: Lippincot Williams and Wilkins, 2007:497-516
   Google Scholar
• Druker B, Guilhot F, O'Brien S, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006;355:2408-17
   PubMed Web of Science ®Google Scholar
• Hochhaus A, O'Brien S, Guilhot F, et al. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia 2009;23:1054-61
   PubMed Web of Science ®Google Scholar
• de Lavallade H, Apperley J, Khorashad J, et al. Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. J Clin Oncol 2008;26:3358-63
   PubMed Web of Science ®Google Scholar
• Druker B, Guilhot F, O'Brien S, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006;355:2408-17
   PubMed Web of Science ®Google Scholar
• NCCN Clinical Practice Guidelines in Oncology: Chronic Myelogenous Leukemia, version 1.2011. Fort Washington, PA: National Comprehensive Cancer Network, 2011
   Google Scholar
• Quintás-Cardama A, Kantarjian H, Jones D, et al. Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapy. Blood 2009;113:6315-21
   PubMed Web of Science ®Google Scholar
• Baccarani M, Cortes J, Pane F, et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 2009;27:6041-51
   PubMed Web of Science ®Google Scholar
• Marin D, Bazeos A, Mahon F, et al. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol 2010;28:2381-8
   PubMed Web of Science ®Google Scholar
• Stone R. Optimizing treatment of chronic myeloid leukemia: a rational approach. Oncologist 2004;9:259-70
   PubMed Web of Science ®Google Scholar
• Lee W, Balu S, Cobden D, et al. Prevalence and economic consequences of medication adherence in diabetes: a systematic literature review. Manag Care Interface 2006;19:31-41
   PubMedGoogle Scholar
• Shenolikar R, Balkrishnan R, Camacho F, et al. Comparison of medication adherence and associated health care costs after introduction of pioglitazone treatment in African Americans versus all other races in patients with type 2 diabetes mellitus: a retrospective data analysis. Clin Ther 2006;28:1199-207
   PubMed Web of Science ®Google Scholar
• Sokol M, McGuigan K, Verbrugge R, Epstein R. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care 2005;43:521-30
   PubMed Web of Science ®Google Scholar
• Darkow T, Henk H, Thomas S, et al. Treatment interruptions and non-adherence with imatinib and associated healthcare costs: a retrospective analysis among managed care patients with chronic myelogenous leukaemia. Pharmacoeconomics 2007;25:481-96
   PubMed Web of Science ®Google Scholar
• Noens L, van Lierde M, De Bock R, et al. Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. Blood 2009;113:5401-11
   PubMed Web of Science ®Google Scholar
• Wu E, Johnson S, Beaulieu N, et al. Healthcare resource utilization and costs associated with non-adherence to imatinib treatment in chronic myeloid leukemia patients. Curr Med Res Opin 2010;26:61-9
   PubMed Web of Science ®Google Scholar
• Breccia M, Efficace F, Alimena G. Imatinib treatment in chronic myelogenous leukemia: What have we learned so far?. Cancer Lett 2011;300:115-21
   PubMed Web of Science ®Google Scholar
• Ulcickas Yood M, Oliveria S et al. Adherence to treatment in patients with chronic myelogenous leukemia during a 10-year time period: a medical record review. Blood 2010;116(21)
   Google Scholar
• Wu E, Guerin A, Yu A, et al. Retrospective real-world comparison of medical visits, costs, and adherence between nilotinib and dasatinib in chronic myeloid leukemia. Curr Med Res Opin 2010;26:2861-9
   PubMed Web of Science ®Google Scholar
• Anstrom K, Reed S, Allen A, et al. Long-term survival estimates for imatinib versus interferon-alpha plus low-dose cytarabine for patients with newly diagnosed chronic-phase chronic myeloid leukemia. Cancer 2004;101:2584-92
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Talpaz M, O'Brien S, et al. Survival benefit with imatinib mesylate versus interferon-alpha-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia. Blood 2006;108:1835-40
   PubMed Web of Science ®Google Scholar
• Roy L, Guilhot J, Krahnke T, et al. Survival advantage from imatinib compared with the combination interferon-alpha plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trials. Blood 2006;108:1478-84
   PubMed Web of Science ®Google Scholar
• Andrade S, Kahler K, Frech F, Chan K. Methods for evaluation of medication adherence and persistence using automated databases. Pharmacoepidemiol Drug Saf 2006;16:565-77
   Google Scholar
• Hess L, Raebel M, Conner D, Malone D. Measurement of adherence in pharmacy administrative databases: a proposal for standard definitions and preferred measures. Ann Pharmacother 2006;40:1280-8
   PubMed Web of Science ®Google Scholar
• Partridge A, Avorn J, Wang P, Winer E. Adherence to therapy with oral antineoplastic agents. J Natl Cancer Inst 2002;94:652-61
   PubMed Web of Science ®Google Scholar
• Partridge A, Wang P, Winer E, Avorn J. Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol 2003;21:602-6
   PubMed Web of Science ®Google Scholar
• Garg R, Kantarjian H, O'Brien S, et al. The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: long-term follow-up. Blood 2009;114:4361-8
   PubMed Web of Science ®Google Scholar
• Hochhaus A, Kantarjian H, Baccarani M, et al. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood 2007;109:2303-9
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Giles F, Bhalla K, et al. Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results. Blood 2011;117:1141-5
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Giles F, Gattermann N, et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood 2007;110:3540-6
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Cortes J, Kim D, et al. Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up. Blood 2009;113:6322-9
   PubMed Web of Science ®Google Scholar
• Pladevall M, Williams L, Potts L, et al. Clinical outcomes and adherence to medications measured by claims data in patients with diabetes. Diabetes Care 2004;27:2800-5
   PubMed Web of Science ®Google Scholar
• Karve S, Cleves M, Helm M, et al. An empirical basis for standardizing adherence measures derived from administrative claims data among diabetic patients. Med Care 2008;46:1125-33
   PubMed Web of Science ®Google Scholar